Category: receptor_pharmacology
Explains the transient blue-tinged or blue-haze vision some users notice 30-60 min after sildenafil (and to a lesser extent vardenafil) — most prominent looking at bright sources or computer screens, and resolving within 4-6 hours. Sildenafil is highly selective for PDE5 (the cGMP-hydrolyzing isoform in vascular smooth muscle that the drug exploits for its erectogenic and pulmonary-hypertension effects), but it cross-inhibits PDE6 — the cGMP-PDE that lives exclusively in retinal photoreceptors and drives phototransduction. PDE5/PDE6 selectivity ratios: sildenafil ~10× (Zhang 2004); vardenafil ~15-20×; tadalafil ~700× (which is why tadalafil rarely produces visual disturbance). In rod and cone outer segments PDE6 hydrolyzes cGMP in response to transducin activation, closing CNG channels and hyperpolarizing the cell — the canonical phototransduction cascade. Sildenafil partially inhibits this cycle, raising baseline cGMP, delaying recovery, and shifting blue-cone (S-cone) responses disproportionately (Jagle 2004 demonstrated dose-dependent transient color-vision perturbation in healthy volunteers). The phenomenon is self-limiting and follows sildenafil's PK closely — peaks at Cmax (~1 h) and clears with elimination (t½ ~4 h). Reports of permanent visual change are exceedingly rare; the Laties 2009 review concluded the visual effects are reversible and dose-dependent. Concern remains for users with retinitis pigmentosa (PDE6 mutations) — these patients should avoid PDE5i. Mechanism is purely pharmacodynamic, distinct from the rare reports of NAION which appear vascular.